Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | MicrobiomeTrials← Back to trialsNCT06529822
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-03-20Est. Completion: 2030-01-31
Enrollment target: 64 participants Locations- Washington University School of Medicine, St Louis, Missouri, United States
Other microbiome trials you might be interested in
Bladder Cancer
The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib…
Houston, United StatesCompleted Mar 2024
Non-muscle-invasive Bladder Cancer
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gem…
Birmingham, United StatesEst. completion Nov 1, 2029
Recruiting
The purpose of this study is to find out what effects durvalumab has on bladder cancer, combined with treatment after co…
Calgary, CanadaEst. completion Oct 31, 2026